Emerging strategies for the identification and targeting of cancer stem cells

Tumor Biology

Volumn 31, Issue 4, 2010, Pages 243-253

  Dou, Jun ^a   Gu, Ning ^a  

^a SOUTHEAST UNIVERSITY   (China)

Author keywords

Cancer stem cells; Challenge; Strategy

Indexed keywords

BETA CATENIN; BETA GALACTOSIDASE; BMI1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CALGRANULIN A; CALGRANULIN B; CD133 ANTIGEN; CD24 ANTIGEN; CELL SURFACE MARKER; DENDRITIC CELL VACCINE; HERMES ANTIGEN; HOE 33342; MICRORNA; MICRORNA 200; MULTIDRUG RESISTANCE PROTEIN 5; ONCOLYTIC ADENOVIRUS; SONIC HEDGEHOG PROTEIN; SYNDECAN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCRISTINE; WNT PROTEIN; WNT2 PROTEIN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ABCG5 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; LIPOPROTEIN; TUMOR PROTEIN;

AGAR MEDIUM; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; BREAST TUMOR; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL KILLING; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CLONOGENESIS; COLON CANCER; COLONY FORMATION; CULTURE MEDIUM; CULTURE TECHNIQUE; DRUG RESISTANCE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GLIOMA; HUMAN; MALIGNANT MELANOMA INITIATING CELL; MELANOMA; METASTASIS; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; REPORTER GENE; SP CELL; THREE DIMENSIONAL CELL CULTURE; TUMOR IMMUNITY; TWO DIMENSIONAL CELL CULTURE; ANIMAL; CELL LINEAGE; CELL SEPARATION; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINEAGE; CELL SEPARATION; HUMANS; LIPOPROTEINS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS;

EID: 77954646313     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-010-0023-y     Document Type: Article

References (111)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100:3983-8.
2. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-8.
3. Singh SK, Hawkins C, Clarke ID. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
4. Pierce GB. Neoplasms, differentiations and mutations. Am J Pathol. 1974;77:103-18.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
6. Schatton T, Frank NY, Frank MH. Identification and targeting of cancer stem cells. Bioessays. 2009;10:1038-49.
7. Potter VR. Phenotypic diversity in experimental hepatomas: the concept of partially blocked ontogeny. The 10th Walter Hubert Lecture. Br J Cancer. 1978;38:1-23.
8. Rowan K. Are cancer stem cells real? After four decades, debate still simmers. JNCI. 2009;101:546-7.
9. Hadnagy A, Gaboury L, Beaulieu R. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res. 2006; 3123:701-10.
10. Piccirillo SG, Vescovi AL. Brain tumour stem cells: possibilities of new therapeutic strategies. Expert Opin Biol Ther. 2007; 7:1129-35.
11. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
12. Kimberly EF, Paola R, Clodia O, Lucio M. The cancer stem cell hypothesis. In: Bagley RG and Teicher BA (eds) Cancer drug discovery and development: stem cells and cancer. LLC:Humana Press Publishing, 2009, pp 3-14.
13. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA. 2002;99:12339-44.
14. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-8.
15. Dou J, Pan M, Wen P, et al. Isolation and identification of cancer stem like cells from murine melanoma cell lines. Cell Mol Immunol. 2007;4:467-72.
16. Dou J, Wen P, Pan M, et al. Identification of tumor stem-like cells in mouse melanoma cell line by analysis characteristics of side population cells. Cell Bio Internat. 2009;33:807-15.
17. Alison MR, Islam S. Attributes of adult stem cells. J Pathol. 2009;217:144-60.
18. Dean M. Cancer stem cells and new therapeutic approaches. In: Sharmila B, editor. Cancer stem cells: identification and targets. New Jersey: John Wiley & Sons, Inc. Publishing; 2009. p. 217-32.
19. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006;66:1883-90.
20. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells: perspectives on current status and future directions. AACR workshop on cancer stem cells. Cancer Res. 2006;66:9339-44.
21. Miraglia S, GodfreyW, Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 1997;90:5013-21.
22. Kusumbe AP, Mali AM, Bapat SA. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells. 2009;27:498-508.
23. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820-4.
24. Yao J, Zhang T, Ren J, Yu M, Wu G. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol Rep. 2009;22:781-7.
25. Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23.
26. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007;445:106-10.
27. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111-15.
28. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol. 2008;214:3-9.
29. Shmelkov JM, Butler AT, Hooper AH, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111-20.
30. Mark A, La B, Mina JB. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest. 2008;118:2021-4.
31. Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev. 2008;4:193-201.
32. Cox CV, Diamanti P, Evely RS, et al. Expression of CD133 on leukemia initiating cells in childhood ALL. Blood. 2009; 113:3287-96.
33. Kumamoto H, Ohki K. Detection of CD133, Bmi-1, and ABCG2 in ameloblastic tumors. J Oral Pathol Med 2009, [Epub ahead of print].
34. Zhu Z, Hao X, Yan M, et al. Cancer stem/progenitor cells are highly enriched in CD133(+)CD44(+) population in hepatocellular carcinoma. Int J Cancer 2009, [Epub ahead of print].
35. Curley MD, Therrien VA, Cummings CL, et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells. 2009;12:2875-83.
36. Yasuda H, Tanaka K, Saigusa S, et al. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep. 2009;22:709-17.
37. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797-806.
38. Zhou XD, Wang XY, Qu FJ. Detection of cancer stem cells from the C6 glioma cell line. J Int Med Res. 2009;37:503-10.
39. Hirschmann-Jax C, Foster AE, Wulf GG, et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA. 2004;101:14228-33.
40. Grichnik JM, Burch JA, Schulteis RD, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol. 2006;126:142-53.
41. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA. 2006;103:11154-9.
42. Wang J, Guo LP, Chen LZ, et al. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007;67:3716-24.
43. Chiba T, Kita K, Zheng YW, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology. 2006;44:240-51.
44. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 2004;101:781-6.
45. Dou J, Li Y, Hu W, et al. Identification of tumor stem like cells in mouse myeloma cell lines. Cell Mol Biol. 2009;55(Suppl): OL1151-60.
46. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65:10946-51.
47. Vega F, Davuluri Y, Cho-Vega, et al. Side population of a murine mantle cell lymphoma model contains tumor-initiating cells responsible for lymphoma maintenance and dissemination. J Cell Mol Med 2009, [Epub ahead of print].
48. Burkert J, Otto WR, Wright NA. Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol. 2008;214:564-73.
49. Xu JX, Morii E, Liu Y, Nakamichi N, Ikeda J, Kimura H, et al. High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population. Exp Cell Res. 2007;313:1877-85.
50. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stemlike cells in the C6 glioma cell line. Proc Natl Acad Sci USA. 2004;101:781-6.
51. Grichnik JM, Burch JA, Schulteis RD, et al. Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol. 2006;126:142-53.
52. Zhang X, Jiang CL, Wang BS, Liu Q, Zhao FS, Dou J. Primarily identification of the cell surface mark of ovarial cancer stem cells in a human ovarian cell line based on sorting side population cells. J Southeast University (Medical Science Edition). 2009;28:800-3.
53. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K, Tang DG. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2-cancer cells are similarly tumorigenic. Cancer Res. 2005;65:6207-19.
54. Kim M, Turnquist H, Jackson J. The multidrug resistance transporter ABCG2 (Breast Cancer Resistance Protein 1) Effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res. 2002;8:22-8.
55. Henriksen U, Gether U, Litman T. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2. J Cell Sci. 2005; 118:1417-26.
56. An Y, Ongkeko WM. ABCG2: the key to chemoresistance in cancer stem cells? Expert Opin Drug Metab Toxicol. 2009;5:1529-42.
57. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65:4320-33.
58. Diah SK, Smitherman PK, Aldridge J, et al. Resistance to mitoxantrone in multidrug-resistant MCF-7 breast cancer cells evaluation og mitoxantrone transport and the role of multidrug resistance protein family proteins. Cancer Res. 2001;61:5461-7.
59. Christgen M, Ballmaier M, Bruchhardt H, von Wasielewski R, Kreipe H, Lehmann U. Identification of a distinct side population of cancer cells in the Cal-51 human breast carcinoma cell line. Mol Cell Biochem. 2007;306:201-12.
60. Graf GA, Li WP, Gerard RD. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest. 2002;110:659-69.
61. Gou S, Liu T, Wang C, et al. Establishment of clonal colonyforming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas. 2007;34:429-35.
62. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-9.
63. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197:461-3.
64. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332-6.
65. Gou S, Liu T, Wang C, Yin T, Li K, Yang M, et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas. 2007;34:429-35.
66. Burkert J, Wright NA, Alison MR. Stem cells and cancer: an intimate relationship. J Pathol. 2006;209:287-97.
67. Chang CC, Sun W, Cruz A, Saitoh M, Tai MH, Trosko JE. A human breast epithelial cell type with stem cell characteristics as target cells for carcinogenesis. Radiat Res. 2001;155:201-7.
68. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efficient tumour formation by single human melanoma cells. Nature. 2008;456:593-8.
69. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851-7.
70. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-36.
71. Ischenko I, Seeliger H, Schaffer M, JauchKW, Bruns CJ. Cancer stem cells: how can we target them? Curr Med Chem. 2008;15:3171-84.
72. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer. 2005;5:744-9.
73. Leah O, Benjamin T, Yibin K. Cancer stem cells and metastasis: emerging themes and therapeutic implications. In: Bagley RG and Teicher BA, (eds) Cancer drug discovery and development: stem cells and cancer. LLC: Humana Press Publishing; 2009, pp 92-109.
74. Leonard Z. Foreword. In: John S Yu, (eds) Cancer stem cells. Humana Press. Heidelberg London New York Publishing, 2009, pp 1-5.
75. ErikssonM, Guse K, Bauerschmitz G, Virkkunen P, et al. Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther. 2007;15:2088-93.
76. Jiang H, Gomez-Manzano C, Aoki H, et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst. 2007;99:1410-14.
77. Ischenko I, Seeliger H, Schaffer M, Jauch KW, Christiane JB. Cancer stem cells: how can we target them? Curr Med Chem. 2008;15:3171-84.
78. Preacok CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci USA. 2007;104:4048-53.
79. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM. WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci USA. 2007;104:618-23.
80. Pu P, Zhang Z, Kang C, et al. Downregulation of Wnt2 and betacatenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009;16:351-61.
81. Malanchi I, Peinado H, Kassen D, et al. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nuture. 2008;452:650-3.
82. Rappa G, Fodstad O, Lorico A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells. 2008;26:3008-17.
83. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345-9.
84. Cuilian J, Dou J. Primarily identification of ovarial cancer stem cells in a human ovarian cell line based on sorting side population cells. A Dissertation of the Academic Degree in Southeast University, China.2009, pp 26-30.
85. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-9.
86. Hurwitz J, Fehrenbacher L, Novonty W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Eng J Med. 2004;350:2335-42.
87. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumourmediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol. 2006;8:1369-75.
88. Sanjay KS, Mohamedi NK, Sadhan M. MicroRNAs in Stem Cells and Cancer Stem Cells. In: John S Yu (eds) Cancer stem cells. Humana Press. Heidelberg London New York Publishing, 2009, 62-80.
89. Shimono Y, Zabala M, Cho RW, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell. 2009;138:592-603.
90. Ryan MO, Dinesh SR, Aadel AC, David B. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immnuol. 2010;10:111-22.
91. Dirks PB. MicroRNAs and parallel stem cell lives. Cell. 2009;138:423-4.
92. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS. MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell. 2009;137:647-58.
93. Ulrike B, Jorg S, Ulrich W, et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008;9:582-9.
94. Ulrich W, Jörg S, Ulrike C, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;12:1487-95.
95. Ji Q, Hao X, Zhang M, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE. 2009;4: e6816-24.
96. Griffith LG, Swartz MA. Capturing complex 3D tissue physiology in vitro. Nat Rev Mol Cell Biol. 2006;7:211-24.
97. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 2007;130:601-10.
98. Nelson CM, Bissell MJ. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 2006;22:287-309.
99. Knight ZA, Shokat KM. Chemical genetics: where genetics and pharmacology meet. Cell. 2007;128:425-30.
100. Hebner C, Weaver VM, Debnath J. Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Annu Rev Pathol. 2008;3:313-39.
101. Tomei AA, Boschetti F, Gervaso F, Swartz MA. 3D collagen cultures under well-defined dynamic strain: a novel strain device with a porous elastomeric support. Biotechnol Bioeng. 2009;103:217-25.
102. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Bissell MJ. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol. 2007;1:84-96.
103. Castelló-Cros R, Khan DR, Simons J, Valianou M, Cukierman E. Staged stromal extracellular 3D matrices differentially regulate breast cancer cell responses through PI3K and beta1-integrins. BMC Cancer. 2009;9:94.
104. Quiros RM, Valianou M, Kwon Y, Brown KM, Godwin AK, Cukierman E. Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. Gynecol Oncol. 2008;110:99-109.
105. Serena P, Gaetano F. Dendritic cell vaccines for cancer stem cells. Stem cells and cancer. In: John S Yu (eds). Cancer stem cells. Humana Press. Heidelberg London New York Publishing; 2009, pp 233-47.
106. Tobias S, Markus HF. Antitumor immunity and cancer stem cells. Ann NY Acad Sci. 2009;1176:154-69.
107. Tobias S, Markus HF. Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res. 2008;21:39-55.
108. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136-51.
109. Pietra G, Manzini C, Vitale M, et al. Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. Inter Immunol. 2009;21:793-801.
110. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160-7.
111. Xu QJ, Liu GT, Yuan XP, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cellassociated antigens. Stem Cells. 2009;27:1734-40.